- Home
- AGEN vs CHPG Comparison
AGEN vs CHPG Comparison
Compare AGEN & CHPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AGEN | CHPG |
|---|---|---|
| Founded | 1994 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.2M | 101.5M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | AGEN | CHPG |
|---|---|---|
| Price | $3.12 | $10.19 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $14.50 | N/A |
| AVG Volume (30 Days) | ★ 639.2K | 8.8K |
| Earning Date | 11-10-2025 | 07-23-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $106,829,000.00 | N/A |
| Revenue This Year | $67.15 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $262.26 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.38 | $9.81 |
| 52 Week High | $7.34 | $10.24 |
Technical Indicators
Market Signals| Indicator | AGEN | CHPG |
|---|---|---|
| Relative Strength Index (RSI) | 26.40 | N/A |
| Support Level | $3.01 | N/A |
| Resistance Level | $4.00 | N/A |
| Average True Range (ATR) | 0.25 | 0.00 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 11.26 | 0.00 |
Price Performance
Historical ComparisonAbout AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About CHPG ChampionsGate Acquisition Corporation Class A Ordinary Share
Championsgate Acquisition Corp is a blank check company.